AbbVie Inks $2.9 Billion Cancer Deal With China’s I-Mab

U.S. drugmaker AbbVie Inc. and Chinese drug developer I-Mab agreed to collaborate on a cancer treatment in a deal that could be worth more than $2.9 billion.